Novel pharmaceutical application of apatinib or pharmaceutically acceptable salt thereof

• Main Authors: DU XUEMEI, CHEN QIAN, LI YAN, YANG ZHIRAN
• Format: Patent
• Language: Chinese; English
• Published: 16.10.2020
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

The invention relates to a novel pharmaceutical application of apatinib or a pharmaceutically acceptable salt thereof, in particular to an application of apatinib or a pharmaceutically acceptable saltthereof in preparation of a medicine for treating malignant mesothelioma. The in-vitro test result shows that apatinib mesylate inhibits MPM cell proliferation and activity, affects the G2/M phase ofthe MPM cell cycle process and remarkably inhibits MPM cell movement and migration; an in-vivo test result shows that the apatinib mesylate obviously reduces the ePCI score and has no influence on the body weight of nude mice. The apatinib has no histological toxicity to lung, spleen, kidney and gastrointestinal tract, only has focal lymphocyte infiltration in liver and myocardial tissues, and has an obvious effect of down-regulating NPM2 gene expression. The new application of apatinib or the pharmaceutically acceptable salt thereof provided by the invention provides an important theoreticalbasis for application of a